Prognostic and Predictive Molecular Markers: Are We Ready for their Clinical Use? The Opinion of a Clinical Biochemist

Caldas C. Molecular assessment of cancer. Br Med J 1998; 316: 1360–3.

Gelmon K.A. , Eisenhauer E.A. , Harris A.L. . Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91: 1281–7.

Bartelink H. , Begg A.C. , Martin J.C. . Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 2000; 6: 2–10.

Gion M. , Gasparini G: Biomarkers as therapeutic targets: toward personalized treatments in oncology. In: Diamandis E.P. , Fritsche H.A. , Lilja H. , Chan D.W. , Schwartz M.K. , eds. Tumor markers: Physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press, 2002; 151–62.

Gion M: Serum tumour markers: from quality control to total quality management. Breast 2000; 9: 306–11.

Pfeffer U. , Fecarotta E. , Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995; 55: 2158–65.

Mosselman S. , Polman J. , Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53.

Horowitz K.B. , Jackson T.A. , Bain D.L. , Richer J.K. , Takimoto G.S. , Tung L. Nuclear receptor coactivators and corepres-sors. Mol Endocrinol 1996; 10: 1167–77.

Zwijsen R.M. , Buckle R.S. , Hijmans E.M. . Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998; 12: 3488–98.

Levenson A.S. , Jordan V.C. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur J Cancer 1999; 35: 1628–39.

Dowsett M. , Cooke T. , Ellis I. . Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000; 36: 170–6.

Press M.F. , Hung G. , Godolphin W. , Slamon D.J. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771–7.

Dittadi R. , Meo S. , Amoroso B. , Gion M. Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay. Cancer Res 1997; 57: 1066–72.

Dittadi R. , Meo S. , Fabris F. . Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 2: 87–96.

Tung-Ping Poon R. , Fan S.T. , Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207–25.

Altman D.G. , Lausen B. , Sauerbrei W. , Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829–35.

Biganzoli E. , Boracchi P. , Daidone M.G. . Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998, 13: 107–23.

Gion M. , Gasparini G: Biological and biochemical factors in the prognosis of breast cancer. In: Dixon J.M. , ed. Breast cancer: Diagnosis and management. Amsterdam: Elsevier 2000; 289–98.

National Committee for Clinical Laboratory Standards. Clinical evaluation of immunoassays; Proposed Guideline. NCCLS document I/LA21-P, Villanova, PA 1999.

Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized trials. JAMA 1998; 279: 1489–91.

Horton R. Medical editors trial amnesty: unreported trial registration form. Lancet 1997; 350: 756–7.

Hayes D.F. , Bast R.C. , Desch C.E. . Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456–66.

Gion M. , Boracchi P. , Biganzoli E. , Daidone M.G. A guide for reviewing submitted manuscripts and indications for the design of translational research studies on biomarkers. Int J Biol Markers 1999, 13: 123–33.

Gasparini G. , Gion M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J Sci Am 2000; 6: 117–31.

Pepe S.M. , Etzioni R. , Feng Z. . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054–61.